External partners

External partners

Bayer believes that by combining its own expertise and knowledge with that of external partners - be it an academic institution, a small biotech or a large pharmaceutical company - we can successfully and sustainably contribute to improving therapies that benefit patients, and foster successful collaborations with our partners.

Partnerships with tradition and along the value chain

With a long tradition of successful partnerships all over the world, Bayer is committed to investing in external innovations.
Complementing our own capabilities by establishing long-term relationships with innovative partners from science and industry is an essential element of our strategy.
With our partners and our global organization, Bayer addresses all phases of the value chain from early research and development through production and marketing.

Some of our partners in the field of oncology across the world are presented here. For details on the collaboration please click on the respective field.

Broad network with experts in cancer research

Beyond our own research efforts in oncology, we have established a broad cooperative network with healthcare professionals, academic research centers, other pharma companies, and innovative biotech organizations around the globe.
The ongoing expansion of this network fosters an open exchange of ideas and helps expand Bayer´s vision of innovative treatment options for patients living with cancer.

Onyx Pharmaceuticals

OncoMed Pharmaceuticals

Ardea Biosciences

German Cancer Research
Center (DKFZ)


Tsinghua University

National University
of Singapore




Broad Institute


Seattle Genetics

Peking University

Structural Genomics Consortium

Structural Genomics Consortium

Sysmex Inostics

Ventana Medical Systems

Click on location!